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Abstract
The aim of this study was to determine the accu-
racy of Bayesian networks in supporting breast 
cancer diagnoses. Systematic review and meta-
analysis were carried out, including articles and 
papers published between January 1990 and 
March 2013. We included prospective and retro-
spective cross-sectional studies of the accuracy 
of diagnoses of breast lesions (target conditions) 
made using Bayesian networks (index test). Four 
primary studies that included 1,223 breast le-
sions were analyzed, 89.52% (444/496) of the 
breast cancer cases and 6.33% (46/727) of the 
benign lesions were positive based on the Bayes-
ian network analysis. The area under the curve 
(AUC) for the summary receiver operating char-
acteristic curve (SROC) was 0.97, with a Q* value 
of 0.92. Using Bayesian networks to diagnose 
malignant lesions increased the pretest prob-
ability of a true positive from 40.03% to 90.05% 
and decreased the probability of a false negative 
to 6.44%. Therefore, our results demonstrated 
that Bayesian networks provide an accurate and 
non-invasive method to support breast cancer 
diagnosis.
Medical Informatics; Bayes Theorem; Breast 
Neoplasms
Resumo
O objetivo deste estudo foi avaliar a acurácia 
das redes bayesianas no apoio ao diagnóstico 
de câncer de mama. Foram realizadas revisão 
sistemática e metanálise, que incluíram artigos 
e relatórios publicados entre Janeiro de 1990 e 
Março de 2013. Foram incluídos estudos trans-
versais prospectivos e retrospectivos que avalia-
ram a acurácia do diagnóstico de lesões de ma-
ma (condição alvo) usando as redes bayesianas 
(teste em avaliação). Quatro estudos primários 
que incluíram 1.223 lesões de mama foram ana-
lisados, 89,52% (444/496) dos casos de câncer de 
mama e 6,33% (46/727) das lesões benignas fo-
ram positivas tendo-se como base a análise das 
redes bayesianas. A área dentro da curva SROC 
(característica de operação do receptor sumária) 
foi 0,97, com um valor Q* de 0,92. O uso de re-
des bayesianas no diagnóstico de lesões malig-
nas aumentou a probabilidade pré-teste para 
um verdadeiro positivo de 40,03% para 90,05% 
e diminuiu a probabilidade de um falso nega-
tivo para 6,44%. Portanto, nossos resultados de-
monstraram que as redes bayesianas oferecem 
um método acurado e não invasivo no apoio ao 
diagnóstico de câncer de mama.
Informática Médica; Teorema de Bayes;  
Neoplasias da Mama
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Introduction
Breast cancer is the most common type of can-
cer in women, and it is also a common cause of 
cancer-related mortality, both in developing and 
developed countries. Approximately 1.4 million 
new cases occurred in 2008 worldwide, repre-
senting 23% of all cancers 1,2. Fortunately, the 
early detection of breast cancer can improve the 
chance of successful treatment and recovery 3.
In recent decades, artificial intelligence has 
become widely accepted in medical applica-
tions 4. One such application is Bayesian net-
works, which are becoming widely used to 
represent knowledge domains in the presence 
of uncertainty from randomness. Bayesian net-
works can be used as an analysis and decision 
aid in the interpretation of the results of a di-
agnostic test (e.g. mammography), signs and 
symptoms when uncertainty is known to be a 
dominant factor 5.
A Bayesian network is a graphical model that 
represents probabilistic relationships among 
variables of interest 6. Such networks consist 
of a qualitative component (i.e., the structural 
model), which provides a visual representation 
of the interactions among variables, and a quan-
titative component (i.e., a set of local probability 
distributions), which permits probabilistic in-
ference. Together, these components determine 
the unique joint probability distribution over 
the variables in a specific problem 7. In clinical 
medical practice, professionals can calculate 
probabilities using Bayes’ theorem without a 
computer for a specific diagnosis with limited 
parameters (i.e., a few conditional probabilities). 
If the factors that modify the probability of dis-
ease have interactions, however, the complexity 
of such calculations can increase exponentially, 
making it difficult to solve without computation-
al support. In this case, Bayesian networks may 
be useful 8.
In the Bayesian networks, the nodes represent 
uncertain variables, and typically, there is a pri-
mary or “root” node that represents the variable 
of interest, other nodes impact the probability of 
that primary node 6,7. For example, in medical 
diagnosis, estimating the probability of an event, 
such as the malignancy of a breast mass (“root” 
node), given a set of evidence (i.e., demograph-
ics, image characteristics, etc.) is a problem that 
can be solved with Bayesian networks 8. Patient 
risk factors, signs, symptoms, and the results of 
diagnostic test are inputs of the system 8.
Each node necessarily contains mutually ex-
clusive and collectively exhaustive instances 6,7. 
Mutually exclusive instances refer to events that 
cannot occur at the same time. For example, if a 
coin toss is the variable of interest, heads and tails 
are the mutually exclusive instances of that vari-
able because they cannot occur simultaneously 8.
When both the structure and probabilities 
are established, the Bayesian network can be 
used to determine the probability of one node 
based upon the available information about 
other conditionally dependent nodes using an 
inference algorithm. Inference is the reasoning 
process used to draw conclusions from available 
evidence based on the principles of probabilistic 
reasoning and Bayes’ theorem 6,7,8.
This theory may be used to differentiate be-
tween benign and malignant breast diseases, 
using radiologists’ descriptions of breast imag-
ing findings, helping to define which patients 
should be referred for biopsy and which should 
not be referred for this procedure 9. These sys-
tems can also perform more complex reasoning 
tasks, such as mammography-histology correla-
tion, and detect sampling error better than ra-
diologists 10. This technique can also be used to 
help the general practitioner to determine which 
breast lesions identified on physical examina-
tion should be directed to mammography or for 
mastologist. It can assist the pathologist to do the 
pathological diagnosis too.
The purpose of this systematic review was to 
assess the accuracy of Bayesian networks in pa-
tients with breast lesions.
Methods
Search strategy
The adopted search strategy was to perform a 
search, between January 1990 and March 2014, 
in the following databases: Medical Literature 
Analysis and Retrieval System Online (MEDLINE) 
through PubMed, Cancer Literature (CancerLit), 
Latin American and Caribbean Health Sciences 
(LILACS), Excerpta Medical Database (Embase), 
SciVerse Scopus (Scopus), Cochrane Cen-
tral Register of Controlled Studies (Cochrane), 
Spanish Bibliographic Index of Health Sciences 
(IBECS), Biological Abstracts (BIOSIS), and Web 
of Science.
We also searched papers in grey literature 
(which includes Google Scholar, published papers 
from conferences, government technical reports, 
and other materials that are not controlled by sci-
entific publishers).
The databases were searched using the key-
words included in the Medical Subject Headings 
(MeSH) and their synonyms, including the follow-
ing terms: “breast neoplasms”, “breast lesions”, 
“breast cancer”, “breast tumor”, “mammary neo-
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plasms”, “mammary cancer”, and “mammary tu-
mor”. The papers with these terms were associ-
ated with the evaluated test, “Bayesian network”, 
and with the terms “sensitivity” and “specificity”. 
The full search strategy will be available from the 
authors upon request.
The “*” symbol was used to allow the recovery 
of all variations of the original words with suffixes. 
The above terms were combined using the Bool-
ean operators “AND”, “OR”, and “NOT”.
The search was limited to studies in human fe-
males. There was no language restriction. The ref-
erence lists from all retrieved primary studies were 
checked. The references cited in meta-analyses, 
guidelines, and comments identified in the pre-
viously mentioned databases were also checked. 
We contacted the authors of the studies published 
with incomplete information; however, we re-
ceived no responses to the e-mails sent.
Study screening and eligibility
The initial analysis of the abstracts and titles iden-
tified by the search strategy in the aforementioned 
databases was independently performed by three 
researchers (M.I.R., P.W.S., and G.D.S.); the assess-
ment of English articles was performed by M.I.R., 
P.W.S., and C.S.S., and articles in other languages 
were assessed by different reviewers, E.P.W. and 
G.D.S. with translations performed as necessary. 
Disagreements about the inclusion or exclusion 
of each study were initially resolved by consen-
sus; when consensus was not possible, differences 
were arbitrarily resolved by L.R.M.
Concordance between the reviewers was com-
puted in primary studies using the Kappa Coeffi-
cient of Agreement (κ) 11,12,13. We used the catego-
ries proposed by Altman in 1991 14.
We included cross-sectional studies that used 
Bayesian networks (i.e., the evaluation test) as di-
agnostic test to assess breast lesions (i.e., the target 
conditions). The diagnostic test evaluation con-
sisted of the results provided by the Bayesian net-
works (i.e., positive or negative).
We analyzed the studies involving women with 
breast tumors (benign or malignant) who had un-
dergone surgery or core biopsy followed by histo-
logical analysis. The reference diagnostic test was 
the result of histological analysis of paraffin-em-
bedded sections; a breast cancer result by a Bayes-
ian network was considered to be correct if it did 
not differ from the histological analysis.
For inclusion in our systematic review, the 
final histological diagnosis of breast lesions had 
to characterize the lesion as benign or malignant. 
The diagnostic being considered was the result of 
the Bayesian networks and was identified as the 
diagnosis with the highest a posteriori probabil-
ity calculated from each study, ie, no matter how 
small the difference between the probabilities of a 
diagnosis of cancer against a diagnosis of benign 
lesion or how big the final probability of cancer; 
thus, a patient whose probability of having a ma-
lignancy of 49% against 51% probability of being 
a false positive could be classified by the Bayesian 
network as breast cancer. However, this method 
has been used successfully in the treatment of 
false-positives and false-negatives 8.
Borderline lesions were included, allowing the 
consideration of the applicability of Bayesian net-
works to the pattern classification boundary 6,7.
In this systematic review, we excluded studies 
presenting exclusively benign or breast cancer as 
the reference standard. Thus, the primary out-
come analyzed was the accuracy of breast lesion 
result by Bayesian network.
Data collection and quality evaluation 
methodology
From the studies, we extracted the data (i.e., de-
sign, location, year, sample, average age, and 
prevalence), outcomes, and Bayesian network 
architectures, including the qualitative part (i.e., 
the description of the input and output nodes), 
the quantitative part (i.e., how to obtain the con-
ditional probabilities), and the software used to 
build the Bayesian network and perform infer-
ence, in addition to the patient characteristics.
M.I.R. and P.W.S. independently abstracted 
data on the prevalence of benign and malignant 
breast lesions, study (year), study design, de-
sign and setting, number of lesions, age in years, 
Bayesian network architecture (description of 
outcomes and inputs) including its design, cut-
off conditional and unconditional probabilities, 
and software used. Other reviewers (E.P.W. and 
L.R.M.) independently extracted data from the 
articles published in languages other than Eng-
lish, and translations were performed when nec-
essary. Disagreements regarding the data extrac-
tion were resolved by consensus initially, and, 
when this was not possible, the differences were 
resolved by S.M.N.
Each reviewer also calculated the pretest prob-
ability (i.e., prevalence), sensitivity, specificity, 
positive and negative likelihood ratios, and post-
test probabilities from the primary studies that 
used Bayesian networks for breast cancer diag-
noses. As previously detailed, the studies that did 
not contain the necessary data to construct a 2x2 
contingency table were excluded.
The methodological quality assessment was 
conducted using the Quality Assessment of Di-
agnostic Accuracy Studies (QUADAS) criteria 
modified by Cochrane, which consists of 11 study 
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characteristics that have the potential to intro-
duce bias. These items were classified as positive 
(without bias), negative (potential bias), or insuf-
ficient information 12,13.
Summary of data and statistical analysis
To assess agreement between each study’s eligi-
bility and methodological quality, and the con-
sistency between the Bayesian network results 
and the paraffin and histological results, we cal-
culated the percentage observed using the κ 11,12.
A 2x2 contingency table was constructed for 
each selected study, and all biopsies were clas-
sified as benign or malignant. We calculated the 
sensitivity, specificity, likelihood ratios, and post-
test probability.
For studies in which one cell of the 2x2 con-
tingency table contained a value of zero, 0.5 was 
added. However, the studies in which zero oc-
curred in two or more cells were excluded from 
the analysis 13,14.
We aimed to produce pooled estimates of 
sensitivity and specificity using a meta-analysis, 
which was performed using the Meta-Disc soft-
ware version 1.4 (developed by the Clinical Bio-
statistics Unit, Hospital Ramón y Cajal, Madrid, 
Spain) 15 and Review Manager (RevMan) version 
5.0.21 (developed at The Nordic Cochrane Cen-
tre, Copenhagen, Denmark) 16.
A bivariate analysis were used to calculate the 
pooled estimates of sensitivity, specificity, and 
likelihood ratios, along with 95% confidence in-
tervals (95%CI) to estimate the values presented 
in the summarized meta-analysis 17,18,19. All mea-
surements that were summarized by the random 
effects model of DerSimonian & Laird 20, which 
considers the presence of heterogeneity in the 
studies, were calculated, and all global averages 
were weighted with 95%CI.
The heterogeneity of the results of sensitivity 
and specificity across studies was analyzed by the 
χ2 distribution with n-1 degrees of freedom, and 
the inconsistency I2 21,22. The heterogeneity of 
the positive and negative likelihood ratios of the 
different studies was examined with the Cochran 
Q test (establishing the weights of the studies by 
the inverse of the variance), the χ2 distribution 
with n-1 degrees of freedom, the inconsistency 
(I2), and χ2 were used to estimate the variation 
between the studies 21,22.
As there was no heterogeneity, a summary 
receiver operating characteristic (SROC) curve 
was generated considering the data from all 
thresholds using the method of Littenberg and 
Moses 22. This curve can change, depend-
ing on the threshold and the ROC curve used 
to define an abnormal test, thereby resulting 
in an expected oscillation between sensitivity 
and specificity.
The SROC curve can be considered an excel-
lent summary graph; however, for the purpose 
of comparison, we calculated the Q* point as an 
additional statistic 18,22. The Q* point is the one 
at which the sensitivity and specificity are equal 
in the SROC, and indicates when a test approxi-
mates the desired performance of 100% sensitiv-
ity and specificity, similar to the area under the 
curve (AUC) for an receiver operating character-
istic (ROC) curve. Higher Q* values are associated 
with better performance in diagnostic tests 18,22. 
The AUC and Q* considered in the SROC curve 
were estimated using the trapezoidal numerical 
integration method Meta-Disc 15.
Results
Identification of studies and eligibility
The process of study selection is shown in Fig-
ure 1. We identified 100 citations in the searched 
databases. After the initial review of titles and 
abstracts, 24 full papers were recovered, four of 
which were considered to be eligible for our sys-
tematic review.
Four primary studies, which included breast 
lesions from 1,223 women, met the inclusion 
criteria and were analyzed (as shown in Table 
1) 10,23,24,25. The overall concordance between 
the eligibility and methodological quality of the 
studies was 84% (κ = 0.67), indicating good agree-
ment 12. There was disagreement, which was 
resolved by consensus, between the reviewers 
on the inclusion and exclusion criteria in these 
four studies.
•	 Study	descriptions
Table 1 provides detailed descriptions of the 
studies, tests, and standards used. The mean par-
ticipant age was found in only one study 10. Two 
studies were performed in the United States 10,24, 
one in Ireland 23, and another in England 25.
Breast cancer was found in 496 cases (preva-
lence of 40.56%, i.e., the number of positive cases 
among all individuals included in the studies, 
considering the positive and negative cases), and 
727 (59.44%) patients had benign lesions. Table 2 
summarizes the results for all studies included in 
the meta-analysis.
The Bayesian network documented in these 
studies had the same possible outcomes (i.e., be-
nign and malignant); however, the nodes repre-
senting the input variables showed different char-
acteristics relevant to breast cancer diagnosis.
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Figure 1
Study selection process.
The Bayesian network in Kahn et al. 24 used 
information from the patients’ histories, such as 
the physical exam and mammography results, 
and the conditional probabilities were obtained 
by reviewing the indexed medical literature, 
census data and statistical health reports, i.e., 
conditional probabilities for architectural distor-
tion, previous biopsy at the same site were esti-
mated as well; values for demographic variables 
were derived from published epidemiological 
data; and statistical studies published in peer-
reviewed radiology journals provided most of the 
data for knowledge base, such as values of condi-
tional probabilities findings and mammographic 
findings for breast cancer. The software used for 
learning conditional probabilities was BNG 26, 
and IDEAL was used for inference 27.
The Bayesian network documented by Ham-
ilton et al. 23 used 10 cytological characteristics 
as input information obtained by fine needle 
aspiration cytology (FNAC), and the conditional 
probability matrices relating each of the diag-
nostic clues and their outcomes to diagnosis (be-
nign, malignant) were defined by a cytopatholo-
gist. The software for generating these Bayes-
ian networks was developed at the University 
of Arizona (USA).
The Bayesian network developed by Cruz-
Ramírez et al. 25 considered the patients’ age 
and 10 cytological features obtained by FNAC; 
the conditional probabilities were obtained in 
an automated way from two databases 28,29,30. 
These databases come from the field of pathol-
ogy, regarding the cytodiagnosis of breast can-
cer using FNAC of the breast lesion; the first 
database, collected retrospectively by a single 
observer with 10 years’ experience of reporting 
FNAC, during 1992-1993. The second database, 
collected prospectively by 19 observers with 5-20 
years’ experience of reporting FNAC, contains 
322 consecutive adequate specimens, during 
1996-1997. The software used for learning con-
ditional probabilities was the Power Constructor 
(CBL2-Learning) 31,32, and Netica software was 
used for inference 33.
The Bayesian network presented by Burnside 
et al 10 consisted of 25 hierarchical descriptors of 
BI-RADS classification 34,35, and the conditional 
probabilities were obtained from indexed medi-
cal literature, i.e., the BI-RADS descriptors links 
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Table 1
Characteristics of the studies included in the systematic review.
Characteristic Study (year) Total
Kahn Jr. et al. 24 
(1997)
Hamilton et al. 23 
(1994)
Cruz-Ramírez et al. 25 
(2007)
Burnside et al. 10 
(2004)






N * 77 40 1,014 92 1,223
Age in years (SD/
range)









Outcomes Benign/Malignant Benign/Malignant Benign/Malignant Benign/Malignant
Inputs Five patient history 
items **; Two physical 
findings ***; 15 
mammographic 
findings
10 cytological features Age; 10 cytological 
features
25 hierarchical 







literature #; Census 




Two databases ### Peer-reviewed 
medical literature 
#
Software BNG 26 (learning); 
IDEAL 27 (inference)
Developed in the 
Optical Sciences 













BI-RADS: Breast Imaging-Reporting and Data System; NA: not available. 
* Number of lesions (malignant, benign and normal tissue); 
** Age at menarche, age at first live birth, number of first-degree relatives with breast cancer, previous biopsy; 
*** Nipple discharge, architectural distortion; 
# The authors of the original references used data from the medical literature to fill the parameters of conditional probabilities 
(dependent relationship  
between the variable and the outcome) and unconditional probabilities (prevalence of breast cancer) of the architecture of 
Bayesian network used; 
## A medical specialist who informed, through interviews, conditional probabilities (dependent relationship between the  
variable and the outcome) and unconditional probabilities (prevalence of breast cancer) of the architecture of Bayesian  
network used; 
### These databases come from the field of pathology, regarding the cytodiagnosis of breast cancer using fine needle  
aspiration cytology (FNAC) of the breast lesion; the first database, collected retrospectively by a single observer with  
10 years’ experience of reporting FNAC, during 1992-1993. The second database, collected prospectively by  
19 observers with 5-20 years’ experience of reporting FNAC, contains 322 consecutive adequate specimens,  
during 1996-1997. Reference test: Histology. 
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Table 2
2x2 contingency table.
Study (year) Bayesian network Sensitivity Specificity
Biopsy positive Biopsy negative
TP FN FP TN
Kahn Jr. et al. 24 (1997) 23 2 6 46 92.0 (74.0-99.0) 88.5 (76.6-95.6)
Hamilton et al. 23 (1994) 17 2 0 21 89.5 (66.9-98.7) 100.0 (83.9-100.0)
Cruz-Ramírez et al. 25 (2007) 381 42 36 555 90.1 (86.8-92.7) 93.9 (91.7-95.7)
Burnside et al. 10 (2004) 23 6 4 59 79.3 (60.3-92.0) 93.7 (84.5-98.2)
Total 444 52 46 681 89.5 (86.5-92.1) 93.7 (91.7-95.3)
FN: false negative; FP: false positive; TN: true negative; TP: true positive.
with diseases of the breast applying probabilities 
derived from the literature. The software used in 
the development of these Bayesian networks was 
the GeNIe Modeling Environment developed at 
the University of Pittsburgh (USA) 36.
We seek with this systematic review to pres-
ent the use of Bayesian networks as a method of 
decision support and diagnosis of breast cancer; 
therefore, despite differences in input variables 
of Bayesian networks of studies included in the 
meta-analysis, all showed the same Bayesian 
networks outcome, were used as decision sup-
port and diagnosis, and used Bayes’ theorem to 
calculate inference and a posteriori probability.
•	 Methodological	quality	assessment
Methodological quality assessments of the 
studies were performed according to a modi-
fied version of QUADAS 11,12 and are illustrated 
in Table 3.
The reviewers disagreed on 3 of the 11 items; 
this disagreement was resolved by consensus. 
The presence of withdrawals from the sample 
was not clarified in all studies; additionally, it was 
not possible to determine whether data interpre-
tation was conducted in a blinded manner in the 
included studies. Fifty percent of the studies did 
not describe whether the clinical information 
available was that used in clinical practice, and 
the remainder showed bias on that item. Addi-
tionally, 25% of the studies did not provide suf-
ficient information to enable an assessment of 
whether the sample was representative, that is, 
whether they considered the patients receiving 
routine tests.
Three studies performed well and received a 
positive rating on at least 8 of the 11 items 10,24,25. 
The inter-observer agreement in the analysis of 
methodological quality with QUADAS was 94% 
(κ = 0.86), indicating a good agreement 14. As de-
scribed above, all disagreements were resolved 
by consensus.
•	 Summary	of	diagnostic	performance
The overall inter-observer agreement between 
the Bayesian networks and the paraffin examina-
tion was 92.4% (95%CI: 90.9%-93.9%) (κ = 0.84), 
indicating a good agreement 14. The overall sen-
sitivity was 89.5% (95%CI: 86.5%-92.1%), and the 
specificity was 93.7% (95%CI: 91.7%-95.3%), as 
shown in Table 2.
The sensitivity shown in Table 2 demonstrates 
that there was no heterogeneity (χ2, p = 0.41), and 
the inconsistency (I2 = 0%) was intermediate 37. 
The specificity plot shown in Table 2 suggests 
that there was no heterogeneity, as assessed by χ2 
(p = 0.19), and the inconsistency (I2 = 36.8%) was 
intermediate 37.
The pooled positive likelihood ratio (Table 
4) was 13.55 (95%CI: 10.25-17.92), meaning that 
a positive result from the Bayesian networks in-
creased the odds that the patient had breast can-
cer (i.e., a true positive, TP) by 13.55 times. We did 
not observe heterogeneity in the Cochran Q test 
(p = 0.4154), at τ2 = 0.0, and there was no incon-
sistency (I2 = 0.0%).
The pooled negative likelihood ratio shown in 
Table 4 was 0.12 (95%CI: 0.09-0.18), a good result 
because it is close to zero and indicates that a 
negative result of Bayesian networks decreases 
the odds of a malignant breast lesion by a factor 
of 0.12. We found no heterogeneity with either 
the Cochran Q test (p = 0.2941) or with τ2 (0.0337) 
and low inconsistency (I2 = 19.2%).
The pretest probability (i.e., prevalence) of 
the presence of cancer increased the probability 
of a positive test result from 40.56% to 90.24% 
(95%CI: 90.19%-90.29%) and a negative result 
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Table 3
Results of the risk of bias assessment for each study, according to Quality Assessment of Diagnostic Accuracy Studies (QUADAS).
Characteristic Kahn Jr. et al. 24  
(1997)
Hamilton et al. 23  
(1994)
Cruz-Ramírez et al. 25 
(2007)
Burnside et al. 10  
(2004)
Representative spectrum + + +
Acceptable reference 
standard
+ + + +
Acceptable delay between 
tests
+ + + +
Partial verification avoided + + + +
Differential verification 
avoided
+ + + +
Incorporation avoided + + + +
Reference standard results 
blinded
+ + + +






+ + + +
Withdrawals explained
+: without bias; -: potential bias; blank: insufficient information.
Table 4
Summary of the likelihood ratios and post-test probabilities (random effects model) 14.
Study (year) Likelihood ratio (95%CI) Post-test probability * (95%CI)
Positive Negative Positive Negative
Kahn Jr. et al.24 (1997) 7.97 (3.72-17.07) 0.09 (0.02- 0.34) 79.37 (78.34-80.40) 4.59 (4.06-5.12)
Hamilton et al. 23 (1994) 38.50 (2.47- 599.32) 0.13 (0.04-0.41) 90.89 (89.48-92.30) 6.44 (5.24-7.64)
Cruz-Ramírez et al. 25 (2007) 14.79 (10.76-20.33) 0.11 (0.08-0.14) 91.38 (91.33-91.43) 6.68 (6.63-6.73)
Burnside et al. 10 (2004) 12.49 (4.75-32.83) 0.22 (0.11-0.45) 85.18 (84.43-85.94) 9.23 (8.62-9.85)
Total 13.55 (10.25-17.92) 0.12 (0.09-0.18) 90.24 (90.19-90.29) 7.80 (7.76-7.84)
95%CI: 95% confidence interval. 
* Values of the calculated post-test probability: Pre-test probability = prevalence = 40.56%, Pre-test odds = prevalence/
(1-prevalence), Post-test odds = LH* x pre-test odds, Post-test probability = post-test odds/(1+post-test odds).
from the Bayesian network decreased the proba-
bility of a FP from 40.56% to 7.8% (95%CI: 7.76%-
7.84%) (Table 4).
In the analysis of breast cancer versus benign 
lesions, the area under the SROC curve shown 
in Figure 2 was high (0.97) 38, supporting the use 
of Bayesian networks in breast cancer diagnosis; 
the Q * point was 0.92. In Figure 2 each point rep-
resents a single study, the middle line is the main 
curve, and other curves (first and third) represent 
the confidence interval.
Discussion
This systematic review is the first to examine the 
accuracy of Bayesian networks in supporting 
breast cancer diagnoses. Our results demonstrat-
ed that this computational model can represent 
a non-invasive and accurate method that can be 
used to support breast cancer diagnosis.
For the development and modeling of Bayes-
ian networks there are dozens of free tools or 
demo versions; however, though there are also 
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Figure 2
Summary Receiver Operating Characteristic curve.
Each point represents a single study, the middle line is the main curve and another curves (first and third) represent  
the confidence interval.
dozens of Bayesian networks applied to support 
the diagnosis of breast cancer presented by the 
scientific literature and included in our system-
atic review 10,23,24,25, these are made available by 
contacting the researchers who developed them 
and are used in the research centers that devel-
oped them.
By the research conducted, we observed the 
absence of cost-effectiveness studies on the use 
of this technology. Computational intelligence 
methods, such as Bayesian networks, have been 
introduced into clinical practice with the prima-
ry aims of assisting physicians in the diagnostic 
process by preparing therapeutic decisions and 
predicting various outcomes 39.
The mathematical formalism for Bayesian 
analysis originated in the theorem proposed by 
Thomas Bayes in 1763; as previously detailed, 
it states that conditional probabilities can be 
obtained through two approaches: (a) using in-
formation derived from expert knowledge or lit-
erature, and (b) the probabilities and structure 
obtained by Bayesian learning from large data-
bases 7. In the past, studies typically used the first 
approach 9. Our systematic review included stud-
ies with both approaches; the specific approach 
used may relate to the period in which the study 
was performed.
Research using this theory to support breast 
cancer diagnosis began in the 1990s with a study 
in Ireland that aimed to determine the diagnosis 
and Bayesian network using information from 
fine needle aspiration 23. That study 23, which 
was included in our systematic review and pub-
lished in 1994, was a pioneer in using this com-
putational model, and despite having not used 
an automated technique for the computation of 
the Bayesian network, that study reported high 
accuracy and favorable results that support its 
use in clinical practice.
Moreover, among the methods used in breast 
cancer diagnosis, mammography is generally 
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considered to be the best method available for 
breast cancer screening. However, some types of 
cancers detected in mammograms are missed 
by radiologists. Systems based on Bayesian net-
works applied to mammography seek to reduce 
false negatives by highlighting suspected areas 
for radiologists 40. This feature was also noted in 
the study by Burnside 10, which is included in our 
systematic review.
A study performed by Laming & Warren 41 
in 2000 reinforces this statement because while 
mammography is the primary method used for 
breast cancer screening, approximately 16% to 
31% of cancers detected in mammograms can be 
missed when interpreted by a single radiologist. 
In this regard, a systematic review performed by 
Taylor & Potts in 2008 42 revealed that the dual 
analysis in which two radiologists assessed the 
image increased the rate of cancer detection by 
3-11 per 100,000 women screened. Thus, sys-
tems based on Bayesian networks can assist the 
analysis of suspicious areas that deserve review 
in those cases when it is not possible for two radi-
ologists to analyze the mammograms 42.
Our systematic review allowed the extraction 
and reconstruction of diagnostic data from cross-
sectional studies. The methodological quality of 
the included studies was high, although some 
QUADAS issues had negative evaluations, such 
as lacking information concerning whether the 
sample was representative, blinding in the use 
of Bayesian networks, lacking relevant clinical 
records, and no record of the subjects who were 
removed from the sample.
Although an extensive and detailed search 
strategy was employed, which enabled retrieval 
of all publications regardless of language, the 
terms used may have contributed to the failure 
to locate certain publications that could be rel-
evant to our systematic review. A bivariate analy-
sis used preserves the two-dimensional nature of 
the diagnostic data and considers the measure-
ment variability within and between studies 19. 
We used the most current guidelines indicated 
in the preparation of systematic reviews as de-
scribed in the Handbook for Systematic Reviews of 
Diagnostic Accuracy of Cochrane 11,12,17,18,19,21,22.
The studies included in our systematic review 
presented a dichotomous outcome for breast 
cancer diagnoses; however, there were some dif-
ferences in the composition of the input nodes. 
The study by Kahn Jr. et al. 24 considered the pa-
tients’ histories and physical findings and some 
mammographic data. Hamilton et al. 23 consid-
ered several cytological characteristics. Cruz-
Ramírez et al. 25 used the age of the patient and 
the cytological characteristics, and Burnside et 
al. 10 considered 25 descriptors to produce hier-
archical classifications in BI-RADS. Despite these 
differences, all considered issues were relevant to 
the breast cancer diagnosis.
Regarding economics, some studies have 
shown that the women treated in public institu-
tions have more advanced stages of the disease, 
less access to modern therapies, and a lower 
survival rate than the patients treated in private 
institutions 43,44. The triple test (physical exami-
nation, mammography, and cytology by fine nee-
dle aspiration) has been employed as a method 
to accurately diagnose palpable breast lesions. 
When the three diagnostic methods are consis-
tent, the elimination of biopsy as a confirmatory 
test is usually recommended and can result in 
reduced spending 43. In this context, artificial in-
telligence techniques, such as Bayesian networks 
using above characteristics, now represent a re-
ality and may decrease the uncertainty present 
in biopsies derived from suspicious nodules, en-
abling the reduction of public health costs 43,44.
Bayesian networks have potential to enhance 
the diagnostic process by instilling consistency 
and repeatability. The use of this system, togeth-
er with pre-interpreted diagnostic information, 
could also provide an effective computer-based 
training system for breast cancer diagnostic 45. 
This comparison does not imply that the Bayes-
ian network could replace the specialist but may 
indicate that technology can calculate diagnos-
tic across many variables, incorporate complex 
dependencies among variables, and aid, for ex-
ample, the radiologists’ interpretations 45.
Our meta-analysis showed that Bayesian net-
works have increased the probability of a breast 
cancer diagnosis by 49.68%, suggesting that this 
type of tool can be useful in evaluating suspicious 
lesions. Our findings also indicate that, given a 
negative diagnosis, Bayesian networks decreased 
the likelihood of false positives by 32.76% sup-
porting their utility in evaluating lesions that are 
deemed to be most likely benign.
In conclusion, probabilistic computer mod-
els like Bayesian networks represents a nonin-
vasive method that may substantially aid physi-
cians attempting to diagnose breast cancer in a 
timely and accurate manner.
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Resumen
El objetivo de este estudio fue evaluar la exactitud de 
las redes bayesianas para apoyar el diagnóstico de cán-
cer de mama. Se realizó una revisión sistemática y un 
metaanálisis, que incluyeron artículos y estudios publi-
cados entre enero de 1990 y marzo de 2013. Se incluye-
ron estudios transversales prospectivos y retrospectivos, 
que evaluaron la exactitud del diagnóstico de lesiones 
mamarias (condición de destino), utilizando redes ba-
yesianas (prueba de evaluación). Se analizaron cuatro 
estudios que incluyeron 1.223 lesiones de mama pri-
marias, un 89,52% (444/496) de los casos de cáncer de 
mama, y un 6,33% (46/727) de las lesiones benignas se 
tomaron como base de análisis de las redes bayesianas. 
El área bajo la curva SROC (característica operativa del 
receptor) fue de un 0,97, con un valor de Q* de un 0,92. 
El uso de las redes bayesianas en el diagnóstico de las 
lesiones malignas aumentó la probabilidad pre test de 
un verdadero positivo desde un 40,03% a un 90,05%, y 
la disminución de la probabilidad de un falso negativo 
de un 6,44%. Por lo tanto, nuestros resultados demues-
tran que las redes bayesianas ofrecen un método preci-
so y no invasivo en el apoyo del diagnóstico del cáncer 
mamario.
Informática Médica; Teorema de Bayes; Neoplasias de 
la Mama
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